Enrique Alvarez, MD, PhD

Professional Titles

• Assistant Medical Director, Neurology

Publications

• Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013 Dec;19(14):1938-42. PubMed PMID: 24277735
• Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug;19(9):1204-8. PubMed PMID: 23322500
• Wang LH, Bucelli RC, Patrick E, Rajderkar D, Alvarez Iii E, Lim MM, Debruin G, Sharma V, Dahiya S, Schmidt RE, Benzinger TS, Ward BA, Ances BM. Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. J Neurol. 2013 Feb;260(2):498-506. PubMed PMID: 22968768
• Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015 Feb 24;84(8):861. PubMed PMID: 25713115
• Alvarez E. Should we start evaluating intrathecal IgM production clinically?. Eur J Neurol. 2014 Dec 30. [Epub ahead of print] PubMed PMID: 25557488
• Hampton C.W., Galperin D., Alvarez E., West M.W. Longitudinally extensive transverse myelitis associated with anti-CRMP-5 in a patient with a mediastinal primary seminoma. Neuroimmunology and Neuroinflammation (Accepted 1/15/15)
• Hampton CW, Galperin D, Alvarez E, West MS. Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma. Neurol Neuroimmunol Neuroinflamm. 2015 Jun;2(3):e82. PubMed PMID: 25798447
• Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015 Feb 24;84(8):861. PubMed PMID: 25713115
• Alvarez E. Should we start evaluating intrathecal IgM production clinically?. Eur J Neurol. 2015 Aug;22(8):1143-4. PubMed PMID: 25557488
• Alvarez E., Piccio L., Tutlam N., Mikesell R.J., Rapp N., Lancia S., Parks B.J., Naismith R.T., Cross A.H. 4. Alvarez, E., Piccio, L., Tutlam, N., Mikesell, R.J., Rapp, N., Lancia, S., Parks, B.J., Naismith, R.T., Cross, A.H. Predicting optimal response to B cell depletion with rituximab in Multiple Sclerosis using CXCL13 index, MRI and clinical measures. Multiple Sclerosis Journal: Experimental, Translational and Clinical. December 2015
• Patel K, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy D, Cross AH. Detection of Cortical Lesions in Multiple Sclerosis: An Efficient New Imaging Approach. Multiple Sclerosis Journal: Experimental, Translational and Clinical. August 2015
• Alvarez E. Should we start evaluating intrathecal IgM production clinically? Eur J Neurol(22)8 pp1143-4 Aug, 2015. DOI10.1111/ene.12625
• Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH. Detection of cortical lesions in multiple sclerosis: A new imaging approach. Multiple sclerosis Journal—Experimental, Translational and Clinical (1) September 1, 2015. DOI 10.1177.2055217315606465
• Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Multiple Sclerosis Journal – Experimental, Translational and Clinical. (1) December 1, 2015. DOI 10.1177/2055217315623800
• Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL. CD40-Mediated NF-kB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. The Journal of Immunology, 2016, 197: 000–000. (Accepted)
• Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep;3(3):2055217317725102. PubMed PMID: 28839949
• Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2017 Aug 1;:272989X17724434. [Epub ahead of print] PubMed PMID: 28806143
• Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e339. PubMed PMID: 28382320
• Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen FJ, Mealy MA, Sorum J, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Jacob A, Chitnis T, and Weinshenker BG. High Risk of Post-partum Relapses in Neuromyelitis Optica Spectrum Disorder. Neurology. 2017 Nov 28;89(22):2238-2244.
• Almuklass AM , Davis L, Hamilton L, Hebert JR, Alvarez E, Enoka RM. Pulse width does not influence the gains achieved with neuromuscular electrical stimulation in people with multiple sclerosis: double-blind, randomized trial. Neurorehabilitation and Neural Repair Accepted December 20th, 2017
• Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Evaluation of a Novel Tool for Assessing patient treatment Goals, preferences and values related to MS Treatment International Journal of MS Care Accepted December 20th, 2017
• Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L. Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. Int J MS Care. 2018 Nov-Dec;20(6):260-267. PubMed PMID: 30568563
• Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2018 Nov 20;27:383-390. [Epub ahead of print] PubMed PMID: 30502644
• Alvarez E, Mowry EM. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes. Mult Scler. 2018 Oct 22;:1352458518794061. [Epub ahead of print] PubMed PMID: 30346221
• Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2018 Oct 3;27:65-73. [Epub ahead of print] PubMed PMID: 30342416
• Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 Aug 30;379(9):846-855. PubMed PMID: 30157388
• Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug;8(4):292-301. PubMed PMID: 30140580
• Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 Jul 15;390:89-93. PubMed PMID: 29801915
• Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging. 2018 Jul;28(4):399-405. PubMed PMID: 29749661
• Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28;89(22):2238-2244. PubMed PMID: 29093070
• Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep;3(3):2055217317725102. PubMed PMID: 28839949
• Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Jan 11. [Epub ahead of print] PubMed PMID: 30635477
• Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin. 2019 Oct-Dec;5(4):2055217319885986. PubMed PMID: 31819803
• Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2019 Nov 6;38:101508. [Epub ahead of print] PubMed PMID: 31715503
• Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L. A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319879134. PubMed PMID: 31667351
• Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabil Neural Repair. 2018 Jan;32(1):84-93. PubMed PMID: 29366377
• Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15;407:116498. PubMed PMID: 31644992
• Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov;36:101402. PubMed PMID: 31542710
• Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2018 Jan;38(1):44-55. PubMed PMID: 28806143
• Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e339. PubMed PMID: 28382320
• Khan M, Ney DE, Kleinschmidt-DeMasters BK, Horton L, Alvarez E, Piquet AL. CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab. Neurol Clin Pract. 2019 Jun;9(3):273-276. PubMed PMID: 31341717
• Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 Jul 15;332:187-197. PubMed PMID: 31077854
• Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14;7(1). PubMed PMID: 30875812
• Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 Feb;6(2):252-262. PubMed PMID: 30847358
• Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD. Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes. Mult Scler J Exp Transl Clin. 2019 Jan-Mar;5(1):2055217319827618. PubMed PMID: 30800417
• Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. Neurol Ther. 2019 Jun;8(1):109-119. PubMed PMID: 30706431
• Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Feb 12;92(7):e723-e732. PubMed PMID: 30635477
• Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L. Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. Int J MS Care. 2018 Nov-Dec;20(6):260-267. PubMed PMID: 30568563
• Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B, on behalf of the MS-MRIUS Study Group. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037.
• Weinkle L, Domen C, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022
• Alvarez E, Mowry E. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS – Yes. Mult Scler. 2019 Feb;25(2):187-188. doi: 10.1177/1352458518794061.
• Chan A, Rose J, Alvarez E, Bar-Or A, Butzkueven H, Fox R, Gold R, Gudesblatt M, Haartsen J, Spelman T, Wright K, Ferraro D, Sola P, Hodgkinson S, Kalincik T, Lechner-Scott J, McGuigan C, Spach K, Chen C, Fam S, Wu F, and Miller C. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world MS patients. Neurology: Clinical Practice MS ID#: NEURCLINPRACT/2019/043323. 22 October 2019
• Kletenic I, Alvarez E, Honce JH, Valdez B, Vollmer TL, Medina LD. Subjective cognitive concern in Multiple Sclerosis is associated with reduced thalamic volume and cortical gray matter volumes. MSJ-ETC 2019
• Medina L, Torres S, Alvarez E, Valdez B, and Nair K. Patient Reported Outcomes in Multiple Sclerosis: Validation of the Neurological Quality of Life (Neuro-QoL) Short Forms. Multiple Sclerosis Journal - Experimental, Translational and Clinical. First published November 26th, 2019. https://doi.org/10.1177/2055217319885986
• Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology. 09 December 2018 https://doi.org/10.1002/acn3.700
• Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32767538
• Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32767531
• Mañago MM, Kline PW, Alvarez E, Christiansen CL. Trunk and pelvis movement compensation in people with multiple sclerosis: Relationships to muscle function and gait performance outcomes. Gait Posture. 2020 May;78:48-53. PubMed PMID: 32200163
• Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin. 2019 Oct-Dec;5(4):2055217319885986. PubMed PMID: 31819803
• Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2020 Feb;38:101508. PubMed PMID: 31715503
• Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. J Med Internet Res. 2021 Oct 6;23(10):e29558. PubMed PMID: 34612826
• Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2021 Oct 4;:13524585211044479. [Epub ahead of print] PubMed PMID: 34605319
• Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L. A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319879134. PubMed PMID: 31667351
• Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, Azevedo C, Calabresi P, Cohen JA, Freeman L, Henry RG, Longbrake EE, Mitra N, Illenberger N, Schindler M, Moreno-Dominguez D, Ramos M, Mowry E, Oh J, Rodrigues P, Chahin S, Kaisey M, Waubant E, Cutter G, Shinohara R, Reich DS, Solomon A, Sicotte NL. Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. Neuroimage Clin. 2021 Sep 23;32:102834. [Epub ahead of print] PubMed PMID: 34592690
• Enoka RM, Almuklass AM, Alenazy M, Alvarez E, Duchateau J. Distinguishing between Fatigue and Fatigability in Multiple Sclerosis. Neurorehabil Neural Repair. 2021 Sep 28;:15459683211046257. [Epub ahead of print] PubMed PMID: 34583577
• Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15;407:116498. PubMed PMID: 31644992
• Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov;36:101402. PubMed PMID: 31542710
• Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurol Clin Pract. 2021 Aug;11(4):358-361. PubMed PMID: 34484934
• Vollmer TL, Nair KV, Williams IM, Alvarez E. Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve. Neurol Clin Pract. 2021 Aug;11(4):342-351. PubMed PMID: 34476126
• Lovett-Racke AE, Yang Y, Liu Y, Gormley M, Kraus E, Graham C, Wray S, Racke MK, Alvarez E, Bass A, Fox E. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. J Neuroimmunol. 2021 Oct 15;359:577676. PubMed PMID: 34364105
• Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct;55:103170. PubMed PMID: 34364034
• Kline PW, Christiansen CL, Hager ER, Alvarez E, Mañago MM. Movement compensations during a step ascent task are associated with stair climbing performance in people with multiple sclerosis. Gait Posture. 2021 Jun;87:27-32. PubMed PMID: 33878510
• Alvarez E, Nair KV, Gorritz M, Bartolome L, Maloney H, Ding Y, Golan T, Wade RL, Kumar R, Su W, Shah R, Russo P. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Mult Scler Relat Disord. 2021 May;50:102858. PubMed PMID: 33799068
• Chan A, Rose J, Alvarez E, Bar-Or A, Butzkueven H, Fox RJ, Gold R, Gudesblatt M, Haartsen J, Spelman T, Wright K, Ferraro D, Sola P, Hodgkinson S, Kalincik T, Lechner-Scott J, McGuigan C, Spach K, Chen C, Fam S, Wu F, Miller C. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020 Dec;10(6):510-519. PubMed PMID: 33510947
• Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Aug 18;46:102454. [Epub ahead of print] PubMed PMID: 33045496
• Nicholas JA, Shin RK, Alvarez E, Hendin B, Nair KV, Lublin FD. Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. Mult Scler Relat Disord. 2021 Apr;49:102715. PubMed PMID: 33486401
• Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020;11:1045. PubMed PMID: 33071934
• Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020;11:1045. PubMed PMID: 33071934
• Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov;46:102454. PubMed PMID: 33045496
• Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Sep;7(9):1466-1476. PubMed PMID: 32767538
• Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 Sep;7(9):1477-1487. PubMed PMID: 32767531
• Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar;8(1):20552173211069359. PubMed PMID: 35024160
• Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608-619. PubMed PMID: 35483387
• Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. PubMed PMID: 34605319
• Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 Aug 25;387(8):704-714. PubMed PMID: 36001711
• Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021;12:799138. PubMed PMID: 35145470
• Kammeyer R, Mizenko C, Sillau S, Richie A, Owens G, Nair KV, Alvarez E, Vollmer TL, Bennett JL, Piquet AL. Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. Front Neurol. 2022;13:689975. PubMed PMID: 35309573
• Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, Kuhle J. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front Immunol. 2022;13:852563. PubMed PMID: 35432382
• Greenberg BM, Bowen JD, Alvarez E, Rodriguez M, Caggiano AO, Warrington AE, Zhao P, Eisen A. A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Mult Scler J Exp Transl Clin. 2022 Apr-Jun;8(2):20552173221091475. PubMed PMID: 35496758
• Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec;68:104143. PubMed PMID: 36031693
• Curran C, Vaitaitis G, Waid D, Volmer T, Alverez E, Wagner DH. Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS). J Neuroimmunol. 2022 Dec 7;374:578008. [Epub ahead of print] PubMed PMID: 36535240
• Wolf, A. B., & Alvarez, E. (2022). Ublituximab: A novel anti-cd20 therapy for multiple sclerosis. US Neurology, 18(2), 117–21. https://doi.org/10.17925/usn.2022.18.2.117
• Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec;26(1):494-502. PubMed PMID: 36970763
• Zhou W, Graner M, Paucek P, Beseler C, Boisen M, Bubak A, Asturias F, George W, Graner A, Ormond D, Vollmer T, Alvarez E, Yu X. Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis. Cell Death Dis. 2023 Apr 8;14(4):254. PubMed PMID: 37031195
• Courter RJ, Alvarez E, Enoka RM, Ahmed AA. Metabolic costs of walking and arm reaching in persons with mild multiple sclerosis. J Neurophysiol. 2023 Apr 1;129(4):819-832. PubMed PMID: 36883754
• Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 Apr;10(4):579-588. PubMed PMID: 36811392
• Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec;68:104143. PubMed PMID: 36031693
• Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 Aug 25;387(8):704-714. PubMed PMID: 36001711
• Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G, Ledreux A, Zizzo Z, Lundt M, Alvarez E, Yu X. Plasma IgG aggregates as biomarkers for multiple sclerosis. Clin Immunol. 2023 Oct 8;256:109801. [Epub ahead of print] PubMed PMID: 37816415
• Mañago MM, Cohen ET, Alvarez E, Hager ER, Owens JG, Bade M. Feasibility of Low-Load Resistance Training Using Blood Flow Restriction for People With Advanced Multiple Sclerosis: A Prospective Cohort Study. Phys Ther. 2023 Oct 10. [Epub ahead of print] PubMed PMID: 37815934
• Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Sep 15;79:105009. [Epub ahead of print] PubMed PMID: 37783194
• Borko TL, Baxter R, Cabrera-Martinez B, Thiruppathi E, Sabalza M, Venkataraman I, Selva S, Rester C, Sillau S, Pastula DM, Bennett JL, Alvarez E, Gross R, Shah A, Kammeyer R, Corboy JR, Kedl RM, Hsieh EWY, Piquet AL. SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients. J Neuroimmunol. 2023 Oct 15;383:578192. PubMed PMID: 37666038
• Giovannoni G, Alvarez E, Tutton E, Hoffmann O, Xu Y, Vermersch P, Oreja-Guevara C, Trojano M, Gold R, Robles-Cedeño R, Khwaja M, Stadler B, Vandercappellen J, Ziemssen T. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis. Digit Health. 2023 Jan-Dec;9:20552076231173531. PubMed PMID: 37205165
• Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, Kuhle J. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front Immunol. 2022;13:852563. PubMed PMID: 35432382
• Kammeyer R, Mizenko C, Sillau S, Richie A, Owens G, Nair KV, Alvarez E, Vollmer TL, Bennett JL, Piquet AL. Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. Front Neurol. 2022;13:689975. PubMed PMID: 35309573
• Col N, Solomon A, Alvarez E, Pbert L, Ionete C, Berrios Morales I, Chester J, Kutz C, Iwuchukwu C, Livingston T, Springmann V, Col HV, Ngo L. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool. Multiple Sclerosis and Related Disorders, 2023 Oct 21 online DOI:https://doi.org/10.1016/j.msard.2023.105092

Professional Memberships

• American Academy of Neurology (AAN), Member
• Colorado Society of Clinical Neurologists (CSCN), Member
• Society for Neuroscience (SFN), Member
• American Medical Association (AMA), Member
• America Society for Neural Transplantation and Repair (ASNTR), Member
• Rocky Mountain Regional Neuroscience Group (RMRNG), Member
• Colorado Medical Association, Member

Practice Locations

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• Center for Neuroscience

Specialty Information

Specialties

• Neurology, Board Certification (2012)
• Neuroimmunology

Conditions & Treatments

• Brain and Nervous System
• Brain and Nervous System - Multiple Sclerosis